Eyenovia, Inc. (EYEN) announced the decision to terminate a phase III study evaluating its investigational drug-device product, MicroPine, as a potential treatment for pediatric progressive myopia. MicroPine is EYEN’s proprietary drug-device combination of low-dose atropine administered using the company’s Optejet dispensing platform.The decision was taken after an independent Data Review Committee (DRC) determined that the phase III CHAPERONE study of MicroPine was unlikely to meet its primary endpoint of ...